Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.355 USD | +1.17% | +6.08% | -33.33% |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Apr. 29 | Altimmune Shares Decline After Guggenheim Downgrade | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.33% | 515M | |
+3.63% | 106B | |
+7.02% | 23.47B | |
-14.59% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.67% | 16.78B | |
+5.17% | 14.41B | |
+35.92% | 12.86B | |
+326.28% | 8.78B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023